

Mundipharma acquires Australia's Tolmar; adds Eligard to its portfolio

21 February 2018 | News

The acquisition includes the oncology medications Eligard and Bi-Eligard -established hormonal therapies indicated for the palliative treatment of advanced prostate cancer



Mundipharma recently announced the acquisition of specialist pharmaceutical company, Tolmar Australia , including exclusive distribution rights for the oncology medication Eligard (leuprorelin acetate) in Australia and New Zealand.

The acquisition includes the oncology medications Eligard and Bi-Eligard -established hormonal therapies indicated for the palliative treatment of advanced prostate cancer. Available in 67 countries, Eligard is currently marketed in the United States, Australia and New Zealand by Tolmar.

The addition of Tolmar's products complements Mundipharma's existing portfolio and growing range of oncology medications," said Raman Singh, CEO Mundipharma. "In advancing this acquisition we have developed a strong understanding of Tolmar's business, its products and their importance to patients."

Mundipharma's oncology products range includes Akynzeo Capsule, ALOXI (palonosetron HCl) Injection and FOLOTYN (pralatrexate injection).

Akynzeo and ALOXI are both used to prevent nausea and vomiting caused by cancer chemotherapy in adult patients. FOLOTYN is an anti-cancer medicine indicated to treat adult patients suffering from relapsed and/or refractory peripheral T-cell lymphoma.

Mr Singh added that synergistic acquisition is a key aspect of Mundipharma's growth strategy, and in Tolmar it had identified a company with a profitable business and high quality products.

"The acquisition of Tolmar Australia demonstrates Mundipharma's commitment and capacity to invest in long term value for patients, customers and partners," added Mr Singh. "Tolmar is an excellent fit for Mundipharma and we are looking forward to building on the success they have achieved so far."

Mr Singh stated that the integration process was already underway and that the company would ensure continuous access for patients and healthcare professionals.